SCHEMBL6026923

SCHEMBL6026923

C[CH]COc1ccc2c(Nc3cnn(CC(=O)Nc4cccc(F)c4F)c3)ncnc2c1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.54
FLT4 P35916 5/20 0.54
FLT3 P36888 3/20 0.54
CSF1R P07333 3/20 0.52
PDGFRA P16234 2/20 0.52
KIT P10721 1/20 0.52
CYP3A4 P08684 1/20 0.48
AURKA O14965 7/20 0.47
AURKB Q96GD4 2/20 0.46
KDR P35968 5/20 0.41
CDK1 P06493 1/20 0.41
FLT1 P17948 1/20 0.41
EGFR P00533 1/20 0.39
ERBB4 Q15303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431027 0.93 PDGFRB (0.53) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL2049819 0.91 PDGFRB (0.64) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL2052748 0.89 PDGFRB (0.55) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL2031479 0.88 PDGFRB (0.59) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL2053159 0.88 PDGFRB (0.57) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL2049575 0.88 PDGFRB (0.57) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL2050160 0.88 PDGFRB (0.57) PDGFRBFLT4FLT3CSF1RPDGFRA
SCHEMBL3427484 0.88 PDGFRB (0.52) PDGFRBFLT4FLT3CSF1RPDGFRA
Hydrochloric Acid SCHEMBL3427687 0.88 PDGFRB (0.56) PDGFRBFLT4FLT3CSF1RPDGFRA
Hydrochloric Acid SCHEMBL3427279 0.88 PDGFRB (0.56) PDGFRBFLT4FLT3CSF1RPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed